A0A0M3M0G7 (A0A0M3M0G7_HUMAN) Homo sapiens (Human)
Programmed cell death 1 protein UniProtKBInterProInteractive Modelling
288 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: Q15116
Available Structures
32 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Complex structure of PD1 and 609A-Fab |
Heteromer Q15116; | 1×THR; 7×GOL; 7×EDO; 2×MG; 1×PEG; 1×CL; | ||||
| Assess | ||||||
| PD-1 in complex with nivolumab Fab |
Heteromer Q15116; | |||||
| Assess | ||||||
| Complex structure of PD-1 and nivolumab-Fab |
Heteromer Q15116; | 1×NAG; | ||||
| Assess | ||||||
| Complex structure of toripalimab-Fab and PD-1 |
Heteromer Q15116; | 2×NAG; 1×NAG; | ||||
| Assess | ||||||
| N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody ca… |
Heteromer Q15116; | 2×NAG; 2×NAG; 3×NAG; | ||||
| Assess | ||||||
| Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant |
Heteromer Q15116; Q9NZQ7; | 1×CL; | ||||
| Assess | ||||||
| PD-1 in complex with Dostarlimab |
Heteromer Q15116; | |||||
| Assess | ||||||
| High-resolution structure of the cemiplimab Fab in complex with PD-1 |
Heteromer Q15116; | |||||
| Assess | ||||||
| High-affinity human PD-1 PD-L2 complex |
Heteromer Q15116; Q9BQ51; | 1×MG; | ||||
| Assess | ||||||
| Crystal structure of Fab of a PD-1 monoclonal antibody MW11-h317 in complex with PD-1 |
Heteromer Q15116; | 1×NAG; 2×NAG; | ||||
| Assess | ||||||
| The complex structure of PD-1 and cemiplimab |
Heteromer Q15116; | |||||
| Assess | ||||||
| PD-1 extracellular domain in complex with Fab fragment from D12 antibody |
Heteromer Q15116; | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor |
Heteromer Q15116; | 4×EDO; | ||||
| Assess | ||||||
| Complex structure of GY-5 Fab and PD-1 |
Heteromer Q15116; | 1×NAG; 2×NAG; | ||||
| Assess | ||||||
| Complex structure of GY-14 and PD-1 |
Heteromer Q15116; | |||||
| Assess | ||||||
| Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candid… |
Heteromer Q15116; | |||||
| Assess | ||||||
| High resolution structure of the human PD-1 in complex with pembrolizumab Fv |
Heteromer Q15116; | |||||
| Assess | ||||||
| hPD-1/NBO1a Fab complex |
Heteromer Q15116; | |||||
| Assess | ||||||
| PD1 signaling receptor bound to FAB Complex |
Heteromer Q15116; | |||||
| Assess | ||||||
| Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1. |
Heteromer Q15116; Q9NZQ7; | 1×NA; | ||||
| Assess | ||||||
| Complex structure of PD-1 and tislelizumab Fab |
Heteromer Q15116; | 3×NAG; | ||||
| Assess | ||||||
| PD-1 in complex with pembrolizumab Fab |
Heteromer Q15116; | |||||
| Assess | ||||||
| Structure of Sasanlimab Fab in complex with PD-1 |
Heteromer Q15116; | 5×GOL; | ||||
| Assess | ||||||
| Human PD-1 ectodomain complexed with Pembrolizumab Fab |
Heteromer Q15116; | |||||
| Assess | ||||||
| Crystal structure of PD-1 in complex with tislelizumab Fab |
Heteromer Q15116; | |||||
| Assess | ||||||
| C-SH2 domain of SHP-2 in complex with phospho-ITSM of PD-1 |
Heteromer Q06124; Q15116; | |||||
| Assess | ||||||
| Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in com… |
Heteromer Q06124; Q15116; | |||||
| Assess | ||||||
| Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in com… |
Heteromer Q06124; Q15116; | |||||
| Assess | ||||||
| Crystal structure of the extracellular domain of human PD-1 | monomer | |||||
| Assess | ||||||
| Human programmed cell death 1 receptor | monomer | |||||
| Assess | ||||||
| Human apo PD-1 triple mutant | monomer | 2×CL; | ||||
| Assess | ||||||
| Human apo PD-1 double mutant | monomer | 2×CL; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6jjp.2.C | monomer | 0.77 | 100.00 | |||
| Assess | ||||||